Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Employed Subjects with Episodic Migraine
NCT03912337Phase 4Terminated
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in episodic migraine comparing Erenumab with Placebo (2 arms). Primary endpoint: Sum of Monthly Changes From Baseline in Modified MIDAS Total Score at 6 months. Started Dec 2019; status: terminated.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03912337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912337.